JAMA oncology 2018-01-11
Consolidative Radiotherapy for Limited Metastatic Non-Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial.
Abstract
Importance
Patterns-of-failure studies suggest that in metastatic non-small-cell lung cancer (NSCLC) sites of gross disease at presentation are the first to progress when treated with chemotherapy. This knowledge has led to increased adoption of local ablative radiation therapy in patients with stage IV NSCLC, though prospective randomized evidence is limited.
Objective
To determine if intervening with noninvasive stereotactic ablative radiotherapy (SAbR) prior to maintenance chemotherapy in patients with non-progressive limited metastatic NSCLC after induction therapy led to significant improvements in progression-free survival (PFS).
Design, setting, and participants
This is a single-institution randomized phase 2 study of maintenance chemotherapy alone vs SAbR followed by maintenance chemotherapy for patients with limited metastatic NSCLC (primary plus up to 5 metastatic sites) whose tumors did not possess EGFR-targetable or ALK-targetable mutations but did achieve a partial response or stable disease after induction chemotherapy.
Interventions
Maintenance chemotherapy or SAbR to all sites of gross disease (including SAbR or hypofractionated radiation to the primary) followed by maintenance chemotherapy.
Main outcomes and measures
The primary end point was PFS; secondary end points included toxic effects, local and distant tumor control, patterns of failure, and overall survival.
Results
A total of 29 patients (9 women and 20 men) were enrolled; 14 patients (median [range] age, 63.5 [51.0-78.0] years) were allocated to the SAbR-plus-maintenance chemotherapy arm, and 15 patients (median [range] age, 70.0 [51.0-79.0] years) were allocated to the maintenance chemotherapy-alone arm. The trial was stopped to accrual early after an interim analysis found a significant improvement in PFS in the SAbR-plus-maintenance chemotherapy arm of 9.7 months vs 3.5 months in the maintenance chemotherapy-alone arm (P = .01). Toxic effects were similar in both arms. There were no in-field failures with fewer overall recurrences in the SAbR arm while those patients receiving maintenance therapy alone had progression at existing sites of disease and distantly.
Conclusions and relevance
Consolidative SAbR prior to maintenance chemotherapy appeared beneficial, nearly tripling PFS in patients with limited metastatic NSCLC compared with maintenance chemotherapy alone, with no difference in toxic effects. The irradiation prevented local failures in original disease, the most likely sites of first recurrence. Furthermore, PFS for patients with limited metastatic disease appeared similar to those patients with a greater metastatic burden, further arguing for the potential benefits of local therapy in limited metastatic settings.
Trial registration
clinicaltrials.gov Identifier: NCT02045446.
Related Questions
In oligometastatic NSCLC with a solitary brain metastasis and lung primary amenable to SBRT, how would you sequence first-line systemic therapy versus local therapy to the lung after treatment of the CNS metastasis?
Would generally favor appropriate first-line systemic therapy whether that be immunotherapy +/- chemo vs. targeted therapy and if at least stable disease at the next surveillance imaging (~3 months), go ahead and consolidate with SBRT. I don't think it would be wrong to do SBRT upfront here but the ...
Do you ever prophylactically treat an asymptomatic bone metastasis to prevent or delay risk of pathologic fracture?
Yes, this is a situation I have encountered before and I think it is very reasonable to deliver prophylactic RT if there is cortical thinning indicating fracture risk, or if there is documented growth of the metastatic lesion, even in the absence of any symptoms to palliate. Another situation in wh...
Do you consider initiating systemic therapy for patients with NSCLC who develop oligometastatic disease and have all known sites of disease treated with SBRT?
This is a very intriguing and challenging question and addresses a not so uncommon clinical scenario when patients present with one or just a few sites of recurrent disease after delivery of what was considered to be definitive therapy. In such contexts many times it appears appealing and appropriat...
Do you offer consolidative thoracic radiation for oligometastatic NSCLC following upfront immunotherapy?
Yes, I do offer consolidation in patients with oligometastatic lung cancer after immunotherapy. Like @Dr. First Last, often these patients are referred to me at "oligoprogression," when one lesion progresses (often the primary or largest site), but most minor lesions appear to be under control. The ...
How do you approach a patient with NSCLC and 3 oligometastatic lesions that are 4-5 cm in muscles of the extremities?
This is a great question which I suspect will lead to a wide range of answers. My thought is that if the indication is strong enough (which could be iffy as these are likely poor prognosis metastatic sites) that I would proceed with SBRT in this setting - the strongest factors in my decision of SBRT...